JPRN-UMIN000004574招募中2 期
Multicenter phase II trial of panitumumab plus irinotecan and S-1 (PIRIS regimen) in patients treated by oxaliplatin-based chemotherapy with K-RAS wild-type advanced colorectal cancer. - Phase II trial of panitumumab plus irinotecan and S-1 (PIRIS regimen) in patients treated by L-OHP-based chemotherapy with advanced colorectal cancer.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)A history of CPT-11 or cetuximab (C225) use. 2)A history of serious drug hypersensitivity or serious drug allergy. 3)Clinically important infection or suspected infection in febrile patients. 4)Diarrhea(watery) or diarrhea that interferes with daily activities for patients with a stoma. 5)Active double cancer. 6)Paralytic or occlusive ileus. 7)Uncontrolled body cavity fluid. 8)Symptomatic brain metastasis. 9)Clinically significant heart disease. 10)Severe pulmonary disease. 11)Gastrointestinal ulceration or bleeding. 12)Central nervous system disorders. 13)Uncontrolled diabetes. 14)Women who are pregnant, lactating, or wish to become pregnant or men who expect babies. 15)Judged to be unsuitable for this trial due to clinically significant mental / psychological disease etc. 16)Under treatment with atazanavir, flucytosine, phenytoin, warfarin potassium 17)Judged to be ineligible by principal investigator for any other reason.
研究者
相似试验
已完成
2 期
Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)colorectal cancerJPRN-UMIN000007658Epidemiological and Clinical research Information Network (ECRIN)80
进行中（未招募）
不适用
A Phase II Clinical Trial of Panitumumab in Combination with Infusional Oxaliplatin and Oral Capecitabine (XELOX) Chemotherapy as 1st line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases - NDPreviously untreated Patients with Colorectal Cancer and Advanced Liver Metastases.MedDRA version: 9.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-002007-41-ITAZIENDA OSPEDALIERA ORDINE MAURIZIANO
进行中（未招募）
不适用
An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer.Ensayo Clínico fase II de Panitumumab combinado con quimioterapia de Irinotecan como tratamiento de segunda linea en sujetos con cáncer colorectal metastásico.EUCTR2006-006363-24-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)80
进行中（未招募）
不适用
Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junctioAdenocarcinoma of the stomach or the gastroesophageal junctionMedDRA version: 14.1Level: LLTClassification code 10017768Term: Gastric cancer stage IV without metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10017767Term: Gastric cancer stage IV with metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018993-20-DEniversitätsklinikum Schleswig-Holstein, Campus Kiel
进行中（未招募）
不适用
Estudio clínico abierto de fase II de panitumumab en combinación con quimioterapiaFOLFIRI como tratamiento de segunda línea en sujetos con cáncer colorrectalmetastásico que expresa KRAS no mutado y que haya progresado ≥ 6 meses despuésde la última dosis de la quimioterapia de primera línea - ACTIVECáncer colorrectal metastásico que expresa KRAS no mutadoEUCTR2009-010975-26-ESAssociació Catalana per a la Recerca Oncológica i les seves implicacions Sanitáries i Socials